CDKN2A, a well-known tumor suppressor, can induce cell cycle arrest in G1 and G2 phases by inhibiting the binding of CDK4 or CDK6 with cyclin D1 and initiating p53-dependent cell cycle arrest. Here, CDK4 is linked to neoplasm.